Sanofi Halts Phase 3 Riliprubart Trial for CIDP
French pharmaceutical giant Sanofi has officially terminated its Phase 3 clinical trial evaluating riliprubart as a treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The decision follows a strategic portfolio review, which led the company to discontinue the program due to shifting internal development priorities. While the trial has been stopped, Sanofi confirmed that this move does not stem from safety or efficacy failures identified within the study data.